Body lice (pediculosis corporis)
Also known as: Pediculosis corporis
Methodology & AI Transparency ⓘ
Body lice (pediculosis corporis) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Body lice (pediculosis corporis) (also termed Pediculosis corporis) (ICD-10-CM B85.1), Bacterial, Viral & Fungal Infections protocols prioritize rapid antigen/NAAT PCR in Body lice (pediculosis corporis) (B85.1: diagnostics) paired with baseline and interval C-Reactive Protein / in Body lice (pediculosis corporis) (B85.1: Procalcitonin) assessment.
- 2 Real-world patient consensus: Mapped to Bacterial, Viral & Fungal Infections under ICD-10-CM B85.1 for Body lice (pediculosis corporis) clinical workups.
- 3 Typical cash cost range: Primary evaluation for Body lice (pediculosis corporis) incorporates rapid antigen/NAAT PCR in Body lice (pediculosis corporis) (B85.1: diagnostics) and symptom diary review.
- 4 Top reported side effects / signs: Longitudinal Body lice (pediculosis corporis) monitoring tracks C-Reactive Protein / in Body lice (pediculosis corporis) (B85.1: Procalcitonin) toward Resolution to baseline (B85.1).
Ask our AI Specialists anything about Body lice (pediculosis corporis)
What Is Body lice (pediculosis corporis)?
For patients presenting with Body lice (pediculosis corporis) (also termed Pediculosis corporis) (ICD-10-CM B85.1), Bacterial, Viral & Fungal Infections protocols prioritize rapid antigen/NAAT PCR in Body lice (pediculosis corporis) (B85.1: diagnostics) paired with baseline and interval C-Reactive Protein / in Body lice (pediculosis corporis) (B85.1: Procalcitonin) assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Body lice (pediculosis corporis) (B85.1) center on or fungal) epithelial in Body lice (pediculosis corporis) (B85.1: invasion). targeted infections & antivirals interventions aim to normalize C-Reactive Protein / in Body lice (pediculosis corporis) (B85.1: Procalcitonin).
Common Symptoms & Clinical Signs
- • Presentation of Body lice (pediculosis corporis) (B85.1): painful vesicular rash in Body lice (pediculosis corporis) (B85.1: in a dermatomal)
- • Secondary Body lice (pediculosis corporis) clinical sign: regional lymph node in Body lice (pediculosis corporis) (B85.1: tenderness or acute)
- • Symptom flares in Body lice (pediculosis corporis) correlating with C-Reactive Protein / in Body lice (pediculosis corporis) (B85.1: Procalcitonin) deviation outside Resolution to baseline (B85.1)
- • Functional infections & antivirals impact requiring rapid antigen/NAAT PCR in Body lice (pediculosis corporis) (B85.1: diagnostics) evaluation (B85.1)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Body lice (pediculosis corporis) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | B85.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: C-Reactive Protein / in Body lice (pediculosis corporis) (B85.1: Procalcitonin) | Resolution to baseline (B85.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Targeted PCR / in Body lice (pediculosis corporis) (B85.1: Culture & Sensitivity) | Pathogen clearance / negative test (B85.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Body lice (pediculosis corporis) (B85.1: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (B85.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Body lice (pediculosis corporis)
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Ketoconazole Cream, 2% Ketoconazole Cream, 2% Generic • RxCUI 203088 | Azole Antifungal | 81% | $0.1616 | $ 15.04 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Body lice (pediculosis corporis))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Potent incretin-based therapy for: What a 5,140-Participant Study Found The side effects related to semaglutide and tirzepatide were primarily of mild-to-moderate severity and mostly gastrointestinal, which was more frequent during the dose-titration period and leveled off during the treatment period. Obesity reviews : an official journal of the International Association for the Study of Obesity • 2024-05-15 • Meta-Analysis | N = 5,140 | 99/100 | PMID 38463003 ↗ |
| New Insights on Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized: What a 2,076-Participant Study Found These integrated analyses did not demonstrate any clinically meaningful impact from ADA occurring after treatment with eptinezumab. Frontiers in immunology • 2021-01-15 • Phase III Randomized Trial | N = 2,076 | 96/100 | PMID 34759933 ↗ |
| New Insights on Time spent in glycaemic control with sustained body weight reduction with: What a 6,246-Participant Study Found In this post hoc analysis, people with T2D experienced substantially longer continuous time in glycaemic control and more sustained body weight reductions with tirzepatide versus placebo and active comparators. Diabetes, obesity & metabolism • 2025-06-15 • Randomized Controlled Trial | N = 6,246 | 96/100 | PMID 40083081 ↗ |
| New Insights on Effects of Mind-Body Exercise on Cognitive Function and Peripheral Blood BDNF in: What a 1,251-Participant Study Found Mind-body exercise is beneficial for improving global cognitive function, verbal fluency, executive function, episodic memory, and short-term memory in older adults with MCI; however, evidence remains insufficient regarding... Geriatrics & gerontology international • 2026-11-15 • Meta-Analysis | N = 1,251 | 94/100 | PMID 42951347 ↗ |
| New Insights on Empagliflozin reduces body weight and indices of adipose distribution in patients: What a 823-Participant Study Found Empagliflozin significantly reduced weight and adiposity indices with the potential to improve cardiometabolic risk among patients with type 2 diabetes. Diabetes & vascular disease research • 2016-03-15 • Randomized Controlled Trial | N = 823 | 93/100 | PMID 26873905 ↗ |
Body lice (pediculosis corporis) Patient Community & “People Like Me” Threads
Filter Body lice (pediculosis corporis) community threads and patient logs by age, biological sex, dosage, and treatment duration.